|
|
Article: Melior Grants Pfizer Access To Multiplexed In Vivo Platform.
- Article from:
- BIOWORLD Today
- Article date:
- November 3, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Staff Writer
Melior Discovery Inc. entered a deal to apply its indications discovery platform to Pfizer Inc. compounds, its 11th collaboration since fully beginning operations less than two years ago.
The deal with New York-based Pfizer followed by about five months a similar agreement with Merck & Co. Inc., under which Melior is applying elements of its in vivo theraTRACE platform to neuroscience compounds from Merck, of Whitehouse Station, N.J. Melior has, or has completed, deals with seven other companies, as well as two nonprofit institutions.
The theraTRACE platform entails multiplexed in vivo assays designed to discover new therapeutics ...